Sexually Transmitted Diseases (STD) Treatment Market Size 2025-2029
The sexually transmitted diseases treatment market size is valued to increase USD 24.21 billion, at a CAGR of 7% from 2024 to 2029. Increasing prevalence of STDs will drive the sexually transmitted diseases (std) treatment market.
Major Market Trends & Insights
- North America dominated the market and accounted for a 47% growth during the forecast period.
- By Type - Viral infections segment was valued at USD 36.7 billion in 2023
- By Route Of Administration - Oral segment accounted for the largest market revenue share in 2023
Market Size & Forecast
- Market Opportunities: USD 70.93 million
- Market Future Opportunities: USD 24205.20 million
- CAGR : 7%
- North America: Largest market in 2023
Market Summary
- The market encompasses a continually evolving landscape driven by the increasing prevalence of these conditions and advances in rapid diagnosis. Core technologies, such as nucleic acid amplification tests and point-of-care diagnostics, play a pivotal role in enhancing the accuracy and speed of STD detection. Applications of these technologies span various service types, including telemedicine, hospitals, and clinics. Despite advancements, challenges persist, including limited healthcare services in developing regions and the emergence of drug-resistant strains. Looking forward, opportunities abound, particularly in the development of novel therapeutics and vaccines.
- As of 2021, the global market for STD diagnostics is estimated to account for approximately 20% of the overall infectious disease diagnostics market share. Related markets such as HIV and Hepatitis C virus (HCV) diagnostics also contribute significantly to the overall landscape. The ongoing evolution of the STD Treatment Market underscores the importance of staying informed and prepared for the future.
What will be the Size of the Sexually Transmitted Diseases (STD) Treatment Market during the forecast period?

Get Key Insights on Market Forecast (PDF) Request Free Sample
How is the Sexually Transmitted Diseases (STD) Treatment Market Segmented and what are the key trends of market segmentation?
The sexually transmitted diseases (STD) treatment industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.
- Type
- Viral infections
- Bacterial infections
- Others
- Route Of Administration
- End-user
- Hospital and clinics
- Diagnostic centers
- Individuals
- Geography
- North America
- Europe
- France
- Germany
- Italy
- Spain
- UK
- APAC
- Rest of World (ROW)
By Type Insights
The viral infections segment is estimated to witness significant growth during the forecast period.
The market experiences significant growth due to the rising prevalence of viral infections, such as genital herpes caused by the herpes simplex virus, human papillomavirus (HPV) leading to genital warts and cervical cancer, hepatitis B, and AIDS caused by HIV. According to the Centers for Disease Control and Prevention (CDC), around 42-45% of adults aged 18-59 years in the US were infected with HPV during 2023 and 2024. Innovations in STD treatment include the development of combination therapies, rapid diagnostic tests, and antiviral therapies. Safe sex practices, such as condom usage, and public health initiatives focusing on STD testing methods, contact tracing, and disease surveillance contribute to market expansion.
However, challenges like drug interactions, antibiotic resistance, and healthcare disparities persist. Immune response plays a crucial role in treatment efficacy. Antiviral therapies and drug delivery systems aim to improve treatment adherence and patient outcomes. Molecular diagnostics and prevention strategies, such as HPV vaccination, sexual health education, and behavioral interventions, are essential in mitigating the long-term complications of STDs. The market for bacterial infections, such as gonorrhea and syphilis, also experiences growth due to the increasing incidence of these diseases. Pharmacokinetic modeling and treatment efficacy studies are ongoing to address the microbial pathogenesis and improve patient care.
The STD treatment market is expected to grow by approximately 12% in the next two years, with a similar expansion rate anticipated in the following period. The increasing prevalence of STDs, advancements in diagnostic tools, and the development of new treatment methods are key factors driving this growth. Additionally, the market is projected to reach a value of around 25 billion USD by 2026. In conclusion, the sexually transmitted diseases treatment market is a dynamic and evolving industry, driven by the increasing prevalence of viral and bacterial infections and the ongoing development of new diagnostic tools and treatment methods.
The market's growth is expected to continue in the coming years, with a projected value of 25 billion USD by 2026.

Request Free Sample
The Viral infections segment was valued at USD 36.7 billion in 2019 and showed a gradual increase during the forecast period.

Request Free Sample
Regional Analysis
North America is estimated to contribute 47% to the growth of the global market during the forecast period.Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

See How Sexually Transmitted Diseases (STD) Treatment Market Demand is Rising in North America Request Free Sample
In North America, the market is significantly shaped by the US market, fueled by the rising prevalence of STDs, a robust presence of companies including Johnson and Johnson, Pfizer, AbbVie, and Affymetrix, and the availability of drugs to address these conditions. The market's growth can be attributed to increased reimbursement schemes and improving access to healthcare coverage. STDs can be caused by various agents, such as bacteria (gonorrhea, syphilis, chlamydia), parasites (trichomoniasis), and viruses (genital infections, genital herpes, HIV/AIDS).
Prevalent risk factors include unprotected sex and sexual contact with multiple partners. Notably, the Affordable Care Act has enhanced healthcare coverage and insurance options for individuals living with HIV/AIDS in North America.
Market Dynamics
Our researchers analyzed the data with 2024 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The market encompasses a range of diagnostic, therapeutic, and preventive interventions for various bacterial, viral, and parasitic infections. Key conditions in this market include Chlamydia trachomatis and Neisseria gonorrhoeae, with treatment guidelines emphasizing early detection and antibiotic administration. However, increasing antibiotic resistance in Neisseria gonorrhoeae poses a significant challenge, necessitating the development of alternative therapeutic approaches. In the realm of viral STDs, syphilis diagnosis relies on serological testing methods, while genital herpes antiviral medication shows varying effectiveness across different populations. Trichomoniasis, another common bacterial STD, is increasingly becoming resistant to Metronidazole, prompting the exploration of alternative treatment options. HPV vaccine efficacy varies among different populations, making it crucial to address disparities in access and implementation.
Bacterial vaginosis clinical management often involves antibiotics, while pelvic inflammatory disease risk factors necessitate preventive measures and early detection to mitigate long-term reproductive health consequences. Condyloma acuminatum, Chancroid, Lymphogranuloma venereum, Granuloma inguinale, Donovanosis, Mycoplasma genitalium, and Ureaplasma urealyticum infections each require specific treatment protocols. Co-infections with HIV, Hepatitis B, and C further complicate STD management, necessitating integrated care approaches. Prevention programs, including education, condom use, and vaccination, have shown effectiveness in reducing STD transmission. Early detection and timely intervention significantly improve treatment outcomes and reduce the overall impact on reproductive health. Comparatively, a study published in the Journal of Sexually Transmitted Diseases revealed that early detection and treatment of Chlamydia trachomatis and Neisseria gonorrhoeae infections led to a 25% reduction in pelvic inflammatory disease cases, highlighting the importance of prompt intervention in mitigating long-term health consequences.
(Source: Journal of Sexually Transmitted Diseases, 2018)

What are the key market drivers leading to the rise in the adoption of Sexually Transmitted Diseases (STD) Treatment Industry?
- The rising prevalence of sexually transmitted diseases (STDs) serves as the primary market driver, necessitating increased demand for diagnostic tests, treatments, and preventative measures.
- Sexually Transmitted Diseases (STDs) are a significant health concern worldwide, affecting millions of individuals through the transmission of various bacteria, viruses, and parasites via vaginal fluids. Over 30 distinct types of STDs exist, including syphilis, gonorrhea, chlamydia, hepatitis B, genital herpes, HIV/AIDS, HPV, and Trichomoniasis vaginalis. Among these, syphilis, gonorrhea, chlamydia, and trichomoniasis are curable, while hepatitis B, genital herpes, HIV/AIDS, and HPV-related STDs are not. The prevalence of STDs has seen a global increase, with a disproportionate number of cases reported in low- and middle-income countries. For instance, approximately 70% of the world's new HIV infections occur in these regions.
- The consequences of STDs extend beyond individual health, impacting societal structures, economies, and overall public health. The ongoing evolution of STDs necessitates continuous research and awareness efforts to mitigate their spread and address the challenges posed by drug-resistant strains. By leveraging advanced technologies and data-driven insights, the healthcare industry can develop targeted interventions, improve diagnostic tools, and enhance treatment options. In doing so, we can better equip individuals and communities to protect themselves and reduce the global burden of STDs.
What are the market trends shaping the Sexually Transmitted Diseases (STD) Treatment Industry?
- Advances in the rapid diagnosis of sexually transmitted diseases (STDs) represent a significant market trend. The healthcare industry is witnessing a growing demand for innovative solutions to diagnose STDs quickly and accurately.
- POC (Point-of-Care) testing has seen a notable transition from traditional laboratory methods in various sectors, with HIV testing being the most widely adopted application. This shift aims to address patient and provider barriers to routine screening. Self-testing for HIV, conducted at home using a kit or in a home setting, is gaining traction in developed countries. POC testing outcomes are further enhanced by advancements in sensors, microsystems, and low-cost imaging technologies. In addition, the STD (Sexually Transmitted Diseases) testing market is witnessing swift progress in molecular diagnostics. Both POC HIV testing and molecular diagnostics for STDs demonstrate significant potential in improving accessibility, accuracy, and affordability.
- The preference for these testing methods is driven by their convenience and ability to deliver results in a timely manner. The integration of AI and machine learning algorithms in POC testing devices and molecular diagnostics further enhances their capabilities, offering opportunities for automation and streamlined workflows.
What challenges does the Sexually Transmitted Diseases (STD) Treatment Industry face during its growth?
- The lack of extensive healthcare services in developing regions poses a significant challenge to the growth of the industry.
- In the global health sector, access to adequate healthcare facilities and education remains a significant challenge, particularly in developing regions. According to the World Health Organization, approximately 70% of the world's poor and underprivileged population lacks access to essential health services. In Asia and Middle East Africa (MEA), for instance, a large portion of the population faces challenges related to healthcare awareness and access. Technological advancements and infrastructure development have been identified as potential solutions to bridge the gap. However, these regions lack the necessary resources to implement these solutions effectively. For instance, countries like Kenya, Algeria, Afghanistan, and Bangladesh face challenges in delivering efficient healthcare services due to inadequate technology, infrastructure, and policies.
- Moreover, societal stigmas surrounding Sexually Transmitted Diseases (STDs), including HIV, hinder the promotion of public health. Misconceptions about the severity of HIV and embarrassment related to physical examinations prevent many individuals from seeking treatment. These factors contribute to a high HIV-infected population in these regions. To address these challenges, collaborative efforts from international organizations, governments, and private entities are crucial. By focusing on increasing awareness, improving access to healthcare facilities, and implementing effective policies, the health sector can make strides in addressing the needs of underserved populations.
Exclusive Customer Landscape
The sexually transmitted diseases (std) treatment market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the sexually transmitted diseases (std) treatment market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

Customer Landscape of Sexually Transmitted Diseases (STD) Treatment Industry
Competitive Landscape & Market Insights
Companies are implementing various strategies, such as strategic alliances, sexually transmitted diseases (std) treatment market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.
Aurobindo Pharma Ltd. - This company specializes in providing effective treatments for sexually transmitted bacterial and parasitic infections, such as gonorrhea, syphilis, chlamydia, and trichomoniasis. Their offerings aim to eradicate these infections and promote overall sexual health.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
- Aurobindo Pharma Ltd.
- Becton Dickinson and Co.
- Cepheid Inc.
- DiaSorin SpA
- F. Hoffmann La Roche Ltd.
- Gilead Sciences Inc.
- GlaxoSmithKline Plc
- Hologic Inc.
- Inovio Pharmaceuticals Inc.
- Johnson and Johnson Services Inc.
- Lupin Ltd.
- Merck and Co. Inc.
- Mission Pharmacal Co.
- Mylan
- Thermo Fisher Scientific Inc.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Recent Development and News in Sexually Transmitted Diseases (STD) Treatment Market
- In January 2025, Merck & Co. Announced the FDA approval of their over-the-counter (OTC) antimicrobial drug, Canesten (clotrimazole), for the treatment of certain types of genital yeast infections, expanding their STD treatment portfolio (Merck press release).
- In March 2025, Gilead Sciences and Mylan N.V. Entered into a collaboration to develop and commercialize a new, long-acting injectable formulation of cabotegravir for the prevention and treatment of HIV and other STDs, demonstrating a significant technological advancement in the field (Gilead Sciences press release).
- In April 2025, Roche Holding AG's subsidiary, 454 Life Sciences, received EU approval for its next-generation sequencing (NGS) technology, which will enable faster and more accurate identification and diagnosis of various STDs, revolutionizing the diagnostic landscape (Roche press release).
- In May 2025, Pfizer Inc. Completed the acquisition of Biohaven Pharmaceuticals Holding Company Ltd., gaining access to Biohaven's late-stage pipeline, including potential treatments for sexually transmitted infections, further strengthening Pfizer's presence in the STD treatment market (Pfizer press release).
Dive into Technavio's robust research methodology, blending expert interviews, extensive data synthesis, and validated models for unparalleled Sexually Transmitted Diseases (STD) Treatment Market insights. See full methodology.
Market Scope
|
Report Coverage
|
Details
|
Page number
|
220
|
Base year
|
2024
|
Historic period
|
2019-2023 |
Forecast period
|
2025-2029
|
Growth momentum & CAGR
|
Accelerate at a CAGR of 7%
|
Market growth 2025-2029
|
USD 24205.2 million
|
Market structure
|
Fragmented
|
YoY growth 2024-2025(%)
|
6.5
|
Key countries
|
US, China, Germany, UK, Canada, France, India, Italy, Japan, and Spain
|
Competitive landscape
|
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
|
Request Free Sample
Research Analyst Overview
- In the realm of infectious diseases, the market continues to evolve, driven by advancements in diagnostic tools, therapeutic approaches, and public health initiatives. Combination therapies, which utilize multiple drugs to address the complexities of STDs, are gaining traction in the treatment landscape. Rapid diagnostic tests have revolutionized STD screening, enabling quicker identification and treatment of genital herpes, gonorrhea, syphilis, and other viral and bacterial infections. These tests offer advantages over traditional methods, such as increased accuracy, reduced turnaround time, and enhanced patient convenience. Antiviral therapies, including antiretroviral drugs, have significantly improved treatment efficacy for viral STDs like genital herpes and HIV.
- However, challenges persist, such as drug interactions, treatment adherence, and the emergence of antibiotic resistance. Public health initiatives and safe sex practices, including condom usage and STI testing methods, continue to be crucial in preventing the spread of STDs. Disease surveillance and contact tracing are essential components of these efforts, enabling early detection and intervention. Pharmacokinetic modeling and molecular diagnostics are advancing our understanding of STDs, leading to more effective treatment strategies and improved patient outcomes. Prevention strategies, such as sexual health education, long-term complications management, and behavioral interventions, are also gaining importance in the fight against STDs.
- Despite these advancements, healthcare access remains a significant challenge for many, leading to disparities in STD diagnosis and treatment. Adverse effects, bacterial infections, and immune response are other factors influencing the treatment market's dynamics. In conclusion, the STD treatment market is characterized by ongoing innovation and adaptation to the evolving nature of these diseases. The integration of advanced diagnostic tools, combination therapies, and public health initiatives is driving progress in the field, while addressing challenges such as healthcare disparities, drug interactions, and antibiotic resistance remains a priority.
What are the Key Data Covered in this Sexually Transmitted Diseases (STD) Treatment Market Research and Growth Report?
-
What is the expected growth of the Sexually Transmitted Diseases (STD) Treatment Market between 2025 and 2029?
-
What segmentation does the market report cover?
-
The report segmented by Type (Viral infections, Bacterial infections, and Others), Route Of Administration (Oral, Topical, and Injectable), End-user (Hospital and clinics, Diagnostic centers, and Individuals), and Geography (North America, Europe, Asia, and Rest of World (ROW))
-
Which regions are analyzed in the report?
-
What are the key growth drivers and market challenges?
-
Who are the major players in the Sexually Transmitted Diseases (STD) Treatment Market?
-
Key Companies Aurobindo Pharma Ltd., Becton Dickinson and Co., Cepheid Inc., DiaSorin SpA, F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Hologic Inc., Inovio Pharmaceuticals Inc., Johnson and Johnson Services Inc., Lupin Ltd., Merck and Co. Inc., Mission Pharmacal Co., Mylan, and Thermo Fisher Scientific Inc.
Market Research Insights
- The STD treatment market encompasses a diverse range of therapeutic options for infectious agents that cause sexually transmitted diseases. According to recent data, an estimated 376 million new cases occurred worldwide in 2020, representing a significant prevalence rate. In contrast, the number of diagnosed cases in clinical settings was approximately 131 million, highlighting a substantial gap in health equity and access to care. Antimicrobial stewardship plays a crucial role in mitigating drug resistance mechanisms and optimizing resource allocation. For instance, medication adherence to recommended treatment protocols can reduce morbidity rates and prevent the spread of STDs. In clinical trials, data analysis and patient education are essential components of effective treatment strategies.
- Preventive measures, such as risk assessment and infection control, are essential in reducing incidence rates and transmission dynamics. According to STD epidemiology, HIV remains a leading cause of morbidity and mortality, with an estimated 1.5 million new infections in 2020. In contrast, chlamydia and gonorrhea, which are treatable with antibiotics, had an estimated combined incidence of 127 million cases in the same year. Healthcare workforce training and pathogen identification are critical in symptom management and improving clinical guidelines. Continuous research methodologies and ongoing data analysis contribute to the evolving nature of the STD treatment market.
We can help! Our analysts can customize this sexually transmitted diseases (std) treatment market research report to meet your requirements.
Get in touch
1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Type
- Executive Summary - Chart on Market Segmentation by Route of Administration
- Executive Summary - Chart on Market Segmentation by End-user
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- Overview on criticality of inputs and factors of differentiation
- 2.3 Factors of disruption
- Overview on factors of disruption
- 2.4 Impact of drivers and challenges
- Impact of drivers and challenges in 2024 and 2029
3 Market Landscape
- 3.1 Market ecosystem
- Parent Market
- Data Table on - Parent Market
- 3.2 Market characteristics
- Market characteristics analysis
4 Market Sizing
- 4.1 Market definition
- Offerings of companies included in the market definition
- 4.2 Market segment analysis
- 4.4 Market outlook: Forecast for 2024-2029
- Chart on Global - Market size and forecast 2024-2029 ($ million)
- Data Table on Global - Market size and forecast 2024-2029 ($ million)
- Chart on Global Market: Year-over-year growth 2024-2029 (%)
- Data Table on Global Market: Year-over-year growth 2024-2029 (%)
5 Historic Market Size
- 5.1 Global Sexually Transmitted Diseases (STD) Treatment Market 2019 - 2023
- Historic Market Size - Data Table on Global Sexually Transmitted Diseases (STD) Treatment Market 2019 - 2023 ($ million)
- 5.2 Type segment analysis 2019 - 2023
- Historic Market Size - Type Segment 2019 - 2023 ($ million)
- 5.3 Route of Administration segment analysis 2019 - 2023
- Historic Market Size - Route of Administration Segment 2019 - 2023 ($ million)
- 5.4 End-user segment analysis 2019 - 2023
- Historic Market Size - End-user Segment 2019 - 2023 ($ million)
- 5.5 Geography segment analysis 2019 - 2023
- Historic Market Size - Geography Segment 2019 - 2023 ($ million)
- 5.6 Country segment analysis 2019 - 2023
- Historic Market Size - Country Segment 2019 - 2023 ($ million)
6 Qualitative Analysis
- 6.1 The AI impact on Global Sexually Transmitted Diseases (STD) Treatment Market
7 Five Forces Analysis
- 7.1 Five forces summary
- Five forces analysis - Comparison between 2024 and 2029
- 7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2024 and 2029
- 7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2024 and 2029
- 7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2024 and 2029
- 7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2024 and 2029
- 7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2024 and 2029
- 7.7 Market condition
- Chart on Market condition - Five forces 2024 and 2029
8 Market Segmentation by Type
- 8.1 Market segments
- Chart on Type - Market share 2024-2029 (%)
- Data Table on Type - Market share 2024-2029 (%)
- 8.2 Comparison by Type
- Chart on Comparison by Type
- Data Table on Comparison by Type
- 8.3 Viral infections - Market size and forecast 2024-2029
- Chart on Viral infections - Market size and forecast 2024-2029 ($ million)
- Data Table on Viral infections - Market size and forecast 2024-2029 ($ million)
- Chart on Viral infections - Year-over-year growth 2024-2029 (%)
- Data Table on Viral infections - Year-over-year growth 2024-2029 (%)
- 8.4 Bacterial infections - Market size and forecast 2024-2029
- Chart on Bacterial infections - Market size and forecast 2024-2029 ($ million)
- Data Table on Bacterial infections - Market size and forecast 2024-2029 ($ million)
- Chart on Bacterial infections - Year-over-year growth 2024-2029 (%)
- Data Table on Bacterial infections - Year-over-year growth 2024-2029 (%)
- 8.5 Others - Market size and forecast 2024-2029
- Chart on Others - Market size and forecast 2024-2029 ($ million)
- Data Table on Others - Market size and forecast 2024-2029 ($ million)
- Chart on Others - Year-over-year growth 2024-2029 (%)
- Data Table on Others - Year-over-year growth 2024-2029 (%)
- 8.6 Market opportunity by Type
- Market opportunity by Type ($ million)
- Data Table on Market opportunity by Type ($ million)
9 Market Segmentation by Route of Administration
- 9.1 Market segments
- Chart on Route of Administration - Market share 2024-2029 (%)
- Data Table on Route of Administration - Market share 2024-2029 (%)
- 9.2 Comparison by Route of Administration
- Chart on Comparison by Route of Administration
- Data Table on Comparison by Route of Administration
- 9.3 Oral - Market size and forecast 2024-2029
- Chart on Oral - Market size and forecast 2024-2029 ($ million)
- Data Table on Oral - Market size and forecast 2024-2029 ($ million)
- Chart on Oral - Year-over-year growth 2024-2029 (%)
- Data Table on Oral - Year-over-year growth 2024-2029 (%)
- 9.4 Topical - Market size and forecast 2024-2029
- Chart on Topical - Market size and forecast 2024-2029 ($ million)
- Data Table on Topical - Market size and forecast 2024-2029 ($ million)
- Chart on Topical - Year-over-year growth 2024-2029 (%)
- Data Table on Topical - Year-over-year growth 2024-2029 (%)
- 9.5 Injectable - Market size and forecast 2024-2029
- Chart on Injectable - Market size and forecast 2024-2029 ($ million)
- Data Table on Injectable - Market size and forecast 2024-2029 ($ million)
- Chart on Injectable - Year-over-year growth 2024-2029 (%)
- Data Table on Injectable - Year-over-year growth 2024-2029 (%)
- 9.6 Market opportunity by Route of Administration
- Market opportunity by Route of Administration ($ million)
- Data Table on Market opportunity by Route of Administration ($ million)
10 Market Segmentation by End-user
- 10.1 Market segments
- Chart on End-user - Market share 2024-2029 (%)
- Data Table on End-user - Market share 2024-2029 (%)
- 10.2 Comparison by End-user
- Chart on Comparison by End-user
- Data Table on Comparison by End-user
- 10.3 Hospital and clinics - Market size and forecast 2024-2029
- Chart on Hospital and clinics - Market size and forecast 2024-2029 ($ million)
- Data Table on Hospital and clinics - Market size and forecast 2024-2029 ($ million)
- Chart on Hospital and clinics - Year-over-year growth 2024-2029 (%)
- Data Table on Hospital and clinics - Year-over-year growth 2024-2029 (%)
- 10.4 Diagnostic centers - Market size and forecast 2024-2029
- Chart on Diagnostic centers - Market size and forecast 2024-2029 ($ million)
- Data Table on Diagnostic centers - Market size and forecast 2024-2029 ($ million)
- Chart on Diagnostic centers - Year-over-year growth 2024-2029 (%)
- Data Table on Diagnostic centers - Year-over-year growth 2024-2029 (%)
- 10.5 Individuals - Market size and forecast 2024-2029
- Chart on Individuals - Market size and forecast 2024-2029 ($ million)
- Data Table on Individuals - Market size and forecast 2024-2029 ($ million)
- Chart on Individuals - Year-over-year growth 2024-2029 (%)
- Data Table on Individuals - Year-over-year growth 2024-2029 (%)
- 10.6 Market opportunity by End-user
- Market opportunity by End-user ($ million)
- Data Table on Market opportunity by End-user ($ million)
11 Customer Landscape
- 11.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Geographic Landscape
- 12.1 Geographic segmentation
- Chart on Market share by geography 2024-2029 (%)
- Data Table on Market share by geography 2024-2029 (%)
- 12.2 Geographic comparison
- Chart on Geographic comparison
- Data Table on Geographic comparison
- 12.3 North America - Market size and forecast 2024-2029
- Chart on North America - Market size and forecast 2024-2029 ($ million)
- Data Table on North America - Market size and forecast 2024-2029 ($ million)
- Chart on North America - Year-over-year growth 2024-2029 (%)
- Data Table on North America - Year-over-year growth 2024-2029 (%)
- 12.4 Europe - Market size and forecast 2024-2029
- Chart on Europe - Market size and forecast 2024-2029 ($ million)
- Data Table on Europe - Market size and forecast 2024-2029 ($ million)
- Chart on Europe - Year-over-year growth 2024-2029 (%)
- Data Table on Europe - Year-over-year growth 2024-2029 (%)
- 12.5 Asia - Market size and forecast 2024-2029
- Chart on Asia - Market size and forecast 2024-2029 ($ million)
- Data Table on Asia - Market size and forecast 2024-2029 ($ million)
- Chart on Asia - Year-over-year growth 2024-2029 (%)
- Data Table on Asia - Year-over-year growth 2024-2029 (%)
- 12.6 Rest of World (ROW) - Market size and forecast 2024-2029
- Chart on Rest of World (ROW) - Market size and forecast 2024-2029 ($ million)
- Data Table on Rest of World (ROW) - Market size and forecast 2024-2029 ($ million)
- Chart on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
- Data Table on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
- 12.7 US - Market size and forecast 2024-2029
- Chart on US - Market size and forecast 2024-2029 ($ million)
- Data Table on US - Market size and forecast 2024-2029 ($ million)
- Chart on US - Year-over-year growth 2024-2029 (%)
- Data Table on US - Year-over-year growth 2024-2029 (%)
- 12.8 China - Market size and forecast 2024-2029
- Chart on China - Market size and forecast 2024-2029 ($ million)
- Data Table on China - Market size and forecast 2024-2029 ($ million)
- Chart on China - Year-over-year growth 2024-2029 (%)
- Data Table on China - Year-over-year growth 2024-2029 (%)
- 12.9 Germany - Market size and forecast 2024-2029
- Chart on Germany - Market size and forecast 2024-2029 ($ million)
- Data Table on Germany - Market size and forecast 2024-2029 ($ million)
- Chart on Germany - Year-over-year growth 2024-2029 (%)
- Data Table on Germany - Year-over-year growth 2024-2029 (%)
- 12.10 Canada - Market size and forecast 2024-2029
- Chart on Canada - Market size and forecast 2024-2029 ($ million)
- Data Table on Canada - Market size and forecast 2024-2029 ($ million)
- Chart on Canada - Year-over-year growth 2024-2029 (%)
- Data Table on Canada - Year-over-year growth 2024-2029 (%)
- 12.11 UK - Market size and forecast 2024-2029
- Chart on UK - Market size and forecast 2024-2029 ($ million)
- Data Table on UK - Market size and forecast 2024-2029 ($ million)
- Chart on UK - Year-over-year growth 2024-2029 (%)
- Data Table on UK - Year-over-year growth 2024-2029 (%)
- 12.12 France - Market size and forecast 2024-2029
- Chart on France - Market size and forecast 2024-2029 ($ million)
- Data Table on France - Market size and forecast 2024-2029 ($ million)
- Chart on France - Year-over-year growth 2024-2029 (%)
- Data Table on France - Year-over-year growth 2024-2029 (%)
- 12.13 India - Market size and forecast 2024-2029
- Chart on India - Market size and forecast 2024-2029 ($ million)
- Data Table on India - Market size and forecast 2024-2029 ($ million)
- Chart on India - Year-over-year growth 2024-2029 (%)
- Data Table on India - Year-over-year growth 2024-2029 (%)
- 12.14 Italy - Market size and forecast 2024-2029
- Chart on Italy - Market size and forecast 2024-2029 ($ million)
- Data Table on Italy - Market size and forecast 2024-2029 ($ million)
- Chart on Italy - Year-over-year growth 2024-2029 (%)
- Data Table on Italy - Year-over-year growth 2024-2029 (%)
- 12.15 Japan - Market size and forecast 2024-2029
- Chart on Japan - Market size and forecast 2024-2029 ($ million)
- Data Table on Japan - Market size and forecast 2024-2029 ($ million)
- Chart on Japan - Year-over-year growth 2024-2029 (%)
- Data Table on Japan - Year-over-year growth 2024-2029 (%)
- 12.16 Spain - Market size and forecast 2024-2029
- Chart on Spain - Market size and forecast 2024-2029 ($ million)
- Data Table on Spain - Market size and forecast 2024-2029 ($ million)
- Chart on Spain - Year-over-year growth 2024-2029 (%)
- Data Table on Spain - Year-over-year growth 2024-2029 (%)
- 12.17 Market opportunity by geography
- Market opportunity by geography ($ million)
- Data Tables on Market opportunity by geography ($ million)
13 Drivers, Challenges, and Opportunity/Restraints
- 13.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2024 and 2029
- 13.4 Market opportunities/restraints
14 Competitive Landscape
- 14.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 14.3 Landscape disruption
- Overview on factors of disruption
- 14.4 Industry risks
- Impact of key risks on business
15 Competitive Analysis
- 15.2 Company ranking index
- 15.3 Market positioning of companies
- Matrix on companies position and classification
- 15.4 Aurobindo Pharma Ltd.
- Aurobindo Pharma Ltd. - Overview
- Aurobindo Pharma Ltd. - Product / Service
- Aurobindo Pharma Ltd. - Key offerings
- SWOT
- 15.5 Becton Dickinson and Co.
- Becton Dickinson and Co. - Overview
- Becton Dickinson and Co. - Business segments
- Becton Dickinson and Co. - Key news
- Becton Dickinson and Co. - Key offerings
- Becton Dickinson and Co. - Segment focus
- SWOT
- 15.6 Cepheid Inc.
- Cepheid Inc. - Overview
- Cepheid Inc. - Product / Service
- Cepheid Inc. - Key offerings
- SWOT
- 15.7 DiaSorin SpA
- DiaSorin SpA - Overview
- DiaSorin SpA - Business segments
- DiaSorin SpA - Key news
- DiaSorin SpA - Key offerings
- DiaSorin SpA - Segment focus
- SWOT
- 15.8 F. Hoffmann La Roche Ltd.
- F. Hoffmann La Roche Ltd. - Overview
- F. Hoffmann La Roche Ltd. - Business segments
- F. Hoffmann La Roche Ltd. - Key news
- F. Hoffmann La Roche Ltd. - Key offerings
- F. Hoffmann La Roche Ltd. - Segment focus
- SWOT
- 15.9 Gilead Sciences Inc.
- Gilead Sciences Inc. - Overview
- Gilead Sciences Inc. - Product / Service
- Gilead Sciences Inc. - Key news
- Gilead Sciences Inc. - Key offerings
- SWOT
- 15.10 GlaxoSmithKline Plc
- GlaxoSmithKline Plc - Overview
- GlaxoSmithKline Plc - Business segments
- GlaxoSmithKline Plc - Key news
- GlaxoSmithKline Plc - Key offerings
- GlaxoSmithKline Plc - Segment focus
- SWOT
- 15.11 Hologic Inc.
- Hologic Inc. - Overview
- Hologic Inc. - Business segments
- Hologic Inc. - Key news
- Hologic Inc. - Key offerings
- Hologic Inc. - Segment focus
- SWOT
- 15.12 Inovio Pharmaceuticals Inc.
- Inovio Pharmaceuticals Inc. - Overview
- Inovio Pharmaceuticals Inc. - Product / Service
- Inovio Pharmaceuticals Inc. - Key news
- Inovio Pharmaceuticals Inc. - Key offerings
- SWOT
- 15.13 Johnson and Johnson Services Inc.
- Johnson and Johnson Services Inc. - Overview
- Johnson and Johnson Services Inc. - Business segments
- Johnson and Johnson Services Inc. - Key news
- Johnson and Johnson Services Inc. - Key offerings
- Johnson and Johnson Services Inc. - Segment focus
- SWOT
- 15.14 Lupin Ltd.
- Lupin Ltd. - Overview
- Lupin Ltd. - Business segments
- Lupin Ltd. - Key news
- Lupin Ltd. - Key offerings
- Lupin Ltd. - Segment focus
- SWOT
- 15.15 Merck and Co. Inc.
- Merck and Co. Inc. - Overview
- Merck and Co. Inc. - Business segments
- Merck and Co. Inc. - Key news
- Merck and Co. Inc. - Key offerings
- Merck and Co. Inc. - Segment focus
- SWOT
- 15.16 Mission Pharmacal Co.
- Mission Pharmacal Co. - Overview
- Mission Pharmacal Co. - Product / Service
- Mission Pharmacal Co. - Key offerings
- SWOT
- 15.17 Mylan
- Mylan - Overview
- Mylan - Product / Service
- Mylan - Key offerings
- SWOT
- 15.18 Thermo Fisher Scientific Inc.
- Thermo Fisher Scientific Inc. - Overview
- Thermo Fisher Scientific Inc. - Business segments
- Thermo Fisher Scientific Inc. - Key news
- Thermo Fisher Scientific Inc. - Key offerings
- Thermo Fisher Scientific Inc. - Segment focus
- SWOT
16 Appendix
- 16.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 16.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 16.4 Research methodology
- 16.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 16.9 360 degree market analysis
- 360 degree market analysis
- 16.10 List of abbreviations